MyTomorrows, an Amsterdam, The Netherlands-based online healthcare platform providing early access to drug innovations, raised €4.5m in its first institutional financing.
The round was led by Balderton Capital and Sofinnova Partners.
The company intends to use the funds to enable expansion into new disease areas and into additional European territories, to develop the platform with tools that identify those patients who will most benefit from the therapies and establish business operations in the US.
Founded by Dr. Ronald Brus, former CEO of Crucell, a vaccine company acquired by Johnson & Johnson for $2.4bn in 2011, MyTomorrows is an online platform that uses existing legal frameworks to facilitate patient/physician access to a number of promising experimental treatments. Although still in development, these medicines have shown initial signs of therapeutic benefit and have an acceptable safety profile.
The platform currently offers drugs in oncology, CNS and orphan diseases.
FinSMEs
10/11/2014